[go: up one dir, main page]

CL2016000180A1 - Antituberculous composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its preparation process - Google Patents

Antituberculous composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its preparation process

Info

Publication number
CL2016000180A1
CL2016000180A1 CL2016000180A CL2016000180A CL2016000180A1 CL 2016000180 A1 CL2016000180 A1 CL 2016000180A1 CL 2016000180 A CL2016000180 A CL 2016000180A CL 2016000180 A CL2016000180 A CL 2016000180A CL 2016000180 A1 CL2016000180 A1 CL 2016000180A1
Authority
CL
Chile
Prior art keywords
antituberculous
pyrazinamide
ethambutol
isoniazid
rifampicin
Prior art date
Application number
CL2016000180A
Other languages
Spanish (es)
Inventor
Kumar Amith
Madavan Bindu
Prassad Kum
Khullar Praveen
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51212860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000180(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CL2016000180A1 publication Critical patent/CL2016000180A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPRIMIDO MONOCAPA PARA EL TRATAMIENTO DE LA TUBERCULOSIS, QUE COMPRENDE A) ISONIAZIDA, PORAZINAMIDA, ETAMBUTOS O UNA SAL DE LOS MISMOS, B) RIFAMPICINA EN POLVO Y C) EXCIPIENTE EXTRAGRANULARES; TAL QUE EL TAMAÑO DE PARTÍCULA ES <0,599NM; PROCESO PARA LA PREPARACIÓN DEL COMPRIMIDO.COMPRESSED MONOCAPA FOR THE TREATMENT OF TUBERCULOSIS, WHICH INCLUDES A) ISONIAZIDA, PORAZINAMIDA, ETAMBUTOS OR A SALT OF THE SAME, B) RIFAMPICINA IN POWDER AND C) EXTRAGRANULAR EXCIPIENT; SUCH AS THE PARTICLE SIZE IS <0.599NM; PROCESS FOR THE PREPARATION OF THE TABLETS.

CL2016000180A 2013-07-26 2016-01-22 Antituberculous composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its preparation process CL2016000180A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3343CH2013 2013-07-26

Publications (1)

Publication Number Publication Date
CL2016000180A1 true CL2016000180A1 (en) 2016-06-24

Family

ID=51212860

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000180A CL2016000180A1 (en) 2013-07-26 2016-01-22 Antituberculous composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its preparation process

Country Status (18)

Country Link
US (1) US9814711B2 (en)
EP (1) EP3024445B1 (en)
JP (1) JP2017501117A (en)
CN (1) CN105407874A (en)
AU (1) AU2014295100B2 (en)
CA (1) CA2918828A1 (en)
CL (1) CL2016000180A1 (en)
HK (1) HK1218721A1 (en)
IL (1) IL243370A0 (en)
MX (1) MX2016001156A (en)
MY (1) MY174007A (en)
PE (1) PE20160238A1 (en)
PH (1) PH12016500118A1 (en)
RU (1) RU2672879C2 (en)
SG (1) SG11201510699WA (en)
TW (1) TW201601716A (en)
WO (1) WO2015011163A1 (en)
ZA (1) ZA201600108B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1218861A1 (en) 2013-07-26 2017-03-17 Sanofi Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
CA3019741A1 (en) 2016-04-08 2017-10-12 Quretech Bio Ab Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
US11129816B2 (en) * 2017-10-05 2021-09-28 Quretech Bio Ab Ring-fused thiazolino 2-pyridones in combination with a drug against tuberculosis
WO2019162964A1 (en) * 2018-02-23 2019-08-29 Indian Institute Of Science Anti-tubercular composition, and combinatorial implementations thereof
CN108186638A (en) * 2018-03-08 2018-06-22 重庆华邦制药有限公司 The pharmaceutical composition of isoniazid
IL313429A (en) * 2021-12-07 2024-08-01 An2 Therapeutics Inc Combinations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1217912A (en) 1997-11-26 1999-06-02 岑冠新 Compound rifapentine preparation and preparation method thereof
MXPA02003596A (en) * 2000-08-09 2003-10-14 Panacea Biotec Ltd Novel pharmaceutical compositions of anti-tubercular drugs and process for their preparation.
WO2002087547A1 (en) * 2001-04-27 2002-11-07 Lupin Limited An improved process for preparation of four-drug anti-tubercular fixed dose combination
RU2195937C1 (en) * 2002-02-06 2003-01-10 НИИ молекулярной медицины ММА им. И.М.Сеченова Combined antituberculosis preparation (rizobutol)
US20050059719A1 (en) 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
WO2005074937A1 (en) * 2004-02-04 2005-08-18 Vinay Ramakant Sapte Oral cyclodextrin complexes of anti-tuberculosis drug
TW201434467A (en) 2005-10-05 2014-09-16 Otsuka Pharma Co Ltd Antituberculous therapeutic drugs and kit containing the same
CN1989966B (en) 2005-12-30 2011-06-08 重庆华邦制药股份有限公司 Pharmaceutical composition comprising rifamoin and isoniazid
CN1857280A (en) 2006-04-11 2006-11-08 济南帅华医药科技有限公司 Slow released compound antituberculotic preparation
KR101197277B1 (en) 2009-02-05 2012-11-05 (주) 벡스코아 Oral Solid Preparation For Treatment And Prevention Of Tuberculosis
AP2012006119A0 (en) 2009-07-31 2012-02-29 Cadila Pharmaceuticals Ltd Pharmaceutical composition of isoniazid.
WO2012013756A2 (en) * 2010-07-28 2012-02-02 Laboratoires Pharma 5 Method for preparing tablets combining rifampicin, isoniazid, pyrazinamide and, optionally, ethambutol
US8470365B2 (en) 2010-07-29 2013-06-25 Taiwan Biotech Co., Ltd. Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom
RU2682178C2 (en) 2013-07-26 2019-03-15 Санофи Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
HK1218861A1 (en) 2013-07-26 2017-03-17 Sanofi Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation

Also Published As

Publication number Publication date
ZA201600108B (en) 2017-04-26
CA2918828A1 (en) 2015-01-29
AU2014295100B2 (en) 2019-01-03
WO2015011163A1 (en) 2015-01-29
SG11201510699WA (en) 2016-01-28
JP2017501117A (en) 2017-01-12
RU2016106336A3 (en) 2018-05-17
RU2016106336A (en) 2017-08-31
PE20160238A1 (en) 2016-05-05
PH12016500118A1 (en) 2016-04-25
EP3024445A1 (en) 2016-06-01
RU2672879C2 (en) 2018-11-20
AU2014295100A1 (en) 2016-02-11
IL243370A0 (en) 2016-02-29
MY174007A (en) 2020-03-03
CN105407874A (en) 2016-03-16
TW201601716A (en) 2016-01-16
HK1218721A1 (en) 2017-03-10
MX2016001156A (en) 2016-04-29
US20160158226A1 (en) 2016-06-09
US9814711B2 (en) 2017-11-14
EP3024445B1 (en) 2019-01-09

Similar Documents

Publication Publication Date Title
CL2016000180A1 (en) Antituberculous composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its preparation process
PE20171105A1 (en) SOLID FORMS OF AN ASK1 INHIBITOR
PH12018501073A1 (en) Eif4-a-inhibiting compounds and methods related thereto
CL2018000318A1 (en) Compounds derived from pyridinone, bromodomain inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer diseases. (divisional application 201600925)
CL2016000241A1 (en) Formulation of syk inhibitors.
MX2017016781A (en) CYCLED SULFAMOYLARILAMIDE DERIVATIVES AND ITS USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B.
MX2016010266A (en) Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy] phenyl}-n&#39;-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use.
MX393954B (en) TITANIUM POWDER CONTAINING NITROGEN IN SOLID SOLUTION, TITANIUM MATERIAL, AND METHOD FOR PRODUCING TITANIUM POWDER CONTAINING NITROGEN IN SOLID SOLUTION.
MX2016011810A (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE.
MX2016004530A (en) Rapamycin for the treatment of lymphangioleiomyomatosis.
CL2016001587A1 (en) Derivative based on 1,2-naphthoquinone and method of preparation thereof.
MX2015015409A (en) Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes.
PH12018501237A1 (en) Isoindole compounds
CL2015002692A1 (en) Novel benzenesulfonamide compounds, method to synthesize them and use of the compounds in medicine and cosmetics.
CL2017000682A1 (en) Novel imidazopyridazine compounds and their use.
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
SV2018005702A (en) 1,3,4-TIADIAZOL COMPOUNDS AND THEIR USE IN CANCER TREATMENT
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
CL2018001408A1 (en) 1,3,4-thiadiazole compounds and their use in the treatment of cancer
IN2014MU00916A (en)
MX2017003469A (en) Macrocyclic rip2 kinase inhibitors.
CL2016001843A1 (en) Use of a composition comprising a) a compound of defined formula (ia) or a salt thereof and b) a pharmaceutically acceptable carrier or excipient to prepare a medicament useful for treating an allergic condition in a mammal.
ECSP16005208A (en) STABLE ANTI-TUBERCULOSIS PHARMACEUTICAL COMPOSITION IN A FORM OF A COATED TABLET INCLUDING ISONIAZID GRANULES AND RIFAPENTINE GRANULES AND THEIR PREPARATION PROCESS
SA516370446B1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
IN2013MU01158A (en)